Literature DB >> 10674281

Muscarinic cholinergic mediation of the GH response to gamma-hydroxybutyric acid: neuroendocrine evidence in normal and parkinsonian subjects.

R Volpi1, P Chiodera, P Caffarra, A Scaglioni, L Malvezzi, A Saginario, V Coiro.   

Abstract

We have recently reported that parkinsonian patients show a significant GH response to gamma-hydroxybutyric acid (GHB), but not to gamma-aminobutyric acid (GABA)-ergic drug administration. In order to establish whether muscarinic cholinergic receptors mediate the GH secretion induced by GHB, normal men and parkinsonian patients were tested with GHB both in the absence and in the presence of the anticholinergic agent, pirenzepine. Both normal controls and parkinsonian patients showed a significant serum GH rise in response to GHB (25 mg/kg body weight p.o.) even though a slightly, but significantly lower response was observed in parkinsonian patients. Pretreatment with pirenzepine (100 mg p.o. 2 h before GHB) completely suppressed the GHB-induced GH release in both normal controls and parkinsonian patients. These data indicate that a cholinergic mechanism mediates the GH response to GHB in normal men. In addition the data indicate that this pathway is preserved in the parkinsonian brain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10674281     DOI: 10.1016/s0306-4530(99)00048-7

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  3 in total

Review 1.  gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.

Authors:  Daniel Pardi; Jed Black
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Central and peripheral metabolic changes induced by gamma-hydroxybutyrate.

Authors:  Gianina Luca; Julie Vienne; Angélique Vaucher; Sonia Jimenez; Mehdi Tafti
Journal:  Sleep       Date:  2015-02-01       Impact factor: 5.849

3.  Butyrate increases intracellular calcium levels and enhances growth hormone release from rat anterior pituitary cells via the G-protein-coupled receptors GPR41 and 43.

Authors:  Maria Consolata Miletta; Vibor Petkovic; Andrée Eblé; Roland A Ammann; Christa E Flück; Primus-E Mullis
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.